Ukr.Biochem.J. 2020; Volume 92, Issue 1, Jan-Feb, pp. 56-65

doi: https://doi.org/10.15407/ubj92.01.056

Profiling of metabolic biomarkers in the serum of prostate cancer patients

03.02.2020   Uncategorized   No comments

F. Ali1, S. Akram1, S. Niaz1,2, N. Wajid1

1Institute of Molecular Biology and Biotechnology (IMBB) & Centre for Research In Molecular Medicine (CRIMM), The University of Lahore, Raiwind Road Lahore, Pakistan;
2Social Security Hospital Multan Chungi, Multan Road, Lahore;
e-mail: Fatima.ali@imbb.uol.edu.pk; fatemei.ali@gmail.com

Received: 26 July 2019; Accepted: 29 November 2019

Prostate cancer (PCa) is the major cause of the death of men population globally. Multiple factors are involved in the initiation and progression of PCa. This study aimed to evaluate different metabolic parameters in the serum of PCa patients. Males of 50 years and above age with the recent diagnosis of PCa (digital rectal examination, and elevated serum prostate-specific antigen (PSA) level) were included in the study. Glucose and serum electrolytes level, lactate dehydrogenase activity, parameters of lipid metabolism and liver and kidney functioning were measured on a fully automated analyzer using standard reagent kits. Oxidative stress was evaluated by measuring MDA, CAT, GSH, and SOD in serum. Detection of C-reactive protein (CRP), insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) was performed by immunoassay. It was shown that serum glucose and HDL levels were lower while total cholesterol, LDL and triglyceride levels were significantly higher in PCa group than in the control group. PCa patients had an elevated level of liver and kidney functional markers. Comparison of the oxidative stress markers in patient and control groups showed significant difference. It was detected that serum levels of CRP, IGF-1 and VEGF were significantly higher in PCa group, compared the control to group (P < 0.05). Low level of glucose and dyslipidemia indices in prostate cancer patients indicated metabolic changes and demonstrated the importance of multiple parameters analysis (free PSA, dyslipidemia, VEGF, IGF-1, CRP, and oxidative stress markers) for early PCa diagnostics.

Keywords: , , , ,

References:

  1. Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018;12(6):1807-1823. PubMed, PubMedCentral, CrossRef
  2. Jaiswal S, Sarmad R, Arora S, Dasaraju R, Sarmad K. Prostate Cancer for the Internist. N Am J Med Sci. 2015;7(10):429-35.  PubMed, PubMedCentral, CrossRef
  3. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371-490. PubMed, CrossRef
  4. Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Publica Mex. 2016;58(2):279-84. PubMed, CrossRef
  5. Batty GD, Kivimäki M, Clarke R, Smith GD, Shipley MJ. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311-8.  PubMed, PubMedCentral, CrossRef
  6. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009;282(2):125-36.  PubMed, PubMedCentral, CrossRef
  7. Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging. 2007;2(2):219-36. PubMed, PubMed
  8. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19. PubMed, PubMed, CrossRef
  9. Yanai Y, Kosaka T, Hongo H, Matsumoto K, Shinojima T, Kikuchi E, Miyajima A, Mizuno R, Mikami S, Jinzaki M, Oya M. Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA. Mol Clin Oncol. 2018; 9(6): 656-660. PubMed, PubMed, CrossRef
  10. Agalliu I, Adebiyi AO, Lounsbury DW, Popoola O, Jinadu K, Amodu O, Paul S, Adedimeji A, Asuzu C, Asuzu M, Ogunbiyi OJ, Rohan T, Shittu OB. The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria. BMC Public Health. 2015;15:425. PubMed, PubMed, CrossRef
  11. Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB Isaacs WB, Platz EA. Do environmental factors modify the genetic risk of prostate cancer? Cancer Epidemiol Biomarkers Prev. 2015;24(1):213-20.  PubMed, PubMed, CrossRef
  12. Hanson ED, Hurley BF. Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training biochemical markers. J Aging Res. 2011;2011:903291.  PubMed, PubMed, CrossRef
  13. Algotar A, Hsu CH, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, Abraham I, Kumar R, Ligibel J, Courneya KS, Thomson C. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. JMIR Res Protoc. 2019;8(2):e12579. PubMed, PubMed, CrossRef
  14. Kim DK, Lee JY, Kim KJ, Hong N, Kim JW, Hah YS, Koo KC, Kim JH, Cho KS. Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(1): 113.  PubMed, PubMed, CrossRef
  15. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349-56.  PubMed, PubMed, CrossRef
  16. Zhang JQ, Geng H, Ma M, Nan XY, Sheng BW. Metabolic Syndrome Components are Associated with Increased Prostate Cancer Risk. Med Sci Monit. 2015; 21: 2387-96.  PubMed, PubMed, CrossRef
  17. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843-57. PubMed, CrossRef
  18. Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19(4):323-332. PubMed, PubMed, CrossRef
  19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29. PubMed, CrossRef
  20. McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol. 2016;13(2):99-107. PubMed, CrossRef
  21. Ruseckaite R, Beckmann K, O’Callaghan M, Roder D, Moretti K, Millar J, Evans S. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. BMC Cancer. 2016; 16: 607.  PubMed, PubMed, CrossRef
  22. Ali F, Naqvi SA, Bismillah M, Wajid N. Comparative analysis of biochemical parameters in diabetic and non-diabetic acute myocardial infarction patients. Indian Heart J.2016; 68(3): 325-31. PubMed, PubMed, CrossRef
  23. He Z, Duan X, Zeng G. Identification of potential biomarkers and pivotal biological pathways for prostate cancer using bioinformatics analysis methods. Peer J. 2019;7:e7872.   PubMed, PubMed, CrossRef
  24. Goldner W. Cancer-Related Hypercalcemia. J Oncol Pract. 2016;12(5):426-32. PubMed, CrossRef
  25. Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800.  PubMed, PubMed, CrossRef
  26. Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307-18. PubMed, PubMed, CrossRef
  27. Pelser C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2013;22(4):697-707.  PubMed, PubMed, CrossRef
  28. Zhang GM, Qin XJ, Zhang HL, Xiao WJ, Zhu Y, Gu CY, Dai B, Shi GH, Ye DW. Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. Asian J Androl. 2015;17(2):239-44. PubMed, PubMed, CrossRef
  29. Wu X, Daniels G, Lee P, Monaco ME. Lipid metabolism in prostate cancer. Am J Clin Exp Urol. 2014;2(2):111-20.  PubMed, PubMedCentral
  30. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-80. PubMed, CrossRef
  31. Bach LA. Endothelial cells and the IGF system. J Mol Endocrinol. 2015;54(1):R1–R13.  PubMed, CrossRef
  32. Roberts E, Cossigny DAF, Quan GMY. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer. 2013; 2013: 418340.  PubMed, PubMedCentral, CrossRef
  33. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006;99(2):392-401. PubMed, CrossRef
  34. Lima GA, Correa LL, Gabrich R, Miranda LC, Gadelha MR. IGF-I, insulin and prostate cancer. Arq Bras Endocrinol Metabol. 2009;53(8):969-75. PubMed, CrossRef
  35. Mattsson JM, Ravela S, Hekim C, Jonsson M, Malm J, Närvänen A, Stenman UH, Koistinen H. Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity. PLoS One. 2014; 9(9): e107819.  PubMed, PubMedCentral, CrossRef
  36. LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem. 2010; 391(4): 333-43. PubMed, PubMedCentral, CrossRef
  37. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Kloppel G, Schmiegel W, Zapf J. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab. 2007; 92(5): 1600-5.  PubMed, CrossRef
  38. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med.2000; 28(12): 1745-1750.  PubMed, CrossRef
  39. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118-26.  PubMed, PubMedCentral, CrossRef
  40. Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, Xu Q. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014; 16(3): 467-71. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.